Index. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035

Transcription

1 Index Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035 B Bacille Calmette-Guerin (BCG) in melanoma, 1008 BCG. See Bacille Calmette-Guerin (BCG) BRAF-mutant melanoma algorithm for, C Chemotherapy for HNM, 1100 Chest x-ray in workup and staging of malignant melanoma, 967 Children cutaneous melanoma arising in, Cutaneous melanoma arising in childhood, high-risk RT for, surviving, See also Melanoma D Dermis unknown primary melanoma in, Desmoplastic melanoma RT for, 1033 E Elective lymphadenectomy in regional lymph node management, Eye(s) melanoma arising on, Surg Clin N Am 94 (2014) surgical.theclinics.com /14/$ see front matter ª 2014 Elsevier Inc. All rights reserved.

2 1128 Index F FDG-PET/CT. See 18-fluoro-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) 18-Fluoro-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in workup and staging of malignant melanoma, 968 G Gender as factor in melanoma, 947 H Head and neck melanoma (HNM), classification and staging of, 1093 clinical presentation of, epidemiology of, history of, 1092 introduction, laboratory investigations of, mucosal RT for, physical examination of, treatment and pathologic staging of, adjuvant therapy, 1100 neck dissection, parotid management, 1097 primary lesion related, reconstruction, cheek, ears, eyelids, 1104 forehead, lips, Mohs surgery, 1108 nose, 1106 scalp, techniques, timing of, 1100 SLNB and lymphatic drainage patterns, HNM. See Head and neck melanoma (HNM) Hyperthermic isolated limb perfusion in melanoma, I IL-2. See Interleukin-2 (IL-2) ILI. See Isolated limb infusion (ILI) Immune adjuvants in melanoma, Immunomodulators in melanoma,

3 Index 1129 Immunosuppression melanoma related to, 952 Immunotherapy in melanoma, Interferon adjuvant therapy with results of, Interleukin-2 (IL-2) in melanoma, Intra-arterial regional perfusion therapies in melanoma, hyperthermic isolated limb perfusion, ILI, Intralesional and topical therapies in melanoma, BCG, 1008 IL-2, PV-10/rose bengal, 1009 T-VEC, Intralesional immunotherapy in melanoma, 1026 Isolated limb infusion (ILI) in melanoma, L Lentigo maligna (LM) RT for, 1032 LM. See Lentigo maligna (LM) LND. See Lymph node dissection (LND) Locoregional therapies in melanoma, See also specific types, e.g. Intra-arterial regional perfusion therapies intra-arterial regional perfusion therapies, intralesional and topical therapies, RT, surgical resection, systemic therapy, 1010 topical agents, 1010 Lymph node dissection (LND) in regional lymph node management, Lymphadenectomy elective in regional lymph node management, Lymphoscintigraphy in regional lymph node management, 981 M Malignant melanoma risk factors for, surgical treatment of

4 1130 Index Malignant (continued) introduction, 973 primary cutaneous melanoma, principles of, regional lymph nodes, workup and staging of, biopsy in principles of, imaging in, laboratory tests in, 969 pathologic analysis in, SLNB in, Melanoma(s), See also specific types, e.g., Neurotropic melanoma age as factor in, arising in eye, arising on mucosal surfaces, BRAF-mutant algorithm for, demographics and trends, early detection of, economic impact of, 946 epidemiology of, gender predilection for, 947 global incidence of, 946 head and neck, See also Head and neck melanoma (HNM) high-risk adjuvant therapy for, defined, impact of, incidence of, 989 introduction, , locoregional therapies in, See also Locoregional therapies, in melanoma malignant, See also Malignant melanoma in non-caucasian populations, anatomy related to, 1116 causes of, clinical presentation of, epidemiology of, 1116 histologic type, interventions for, 1123 introduction, outcomes of, stage at diagnosis, in older persons, 948 prevalence of, 963 prevention of, 953 primary cutaneous management of, race as factor in, recurrence of diagnosis and management,

5 Index 1131 local, satellite, and in-transit recurrence, 998 local scar recurrence, 997 metastatic recurrence, regional recurrence, 998 risk factors for, , exposures, host factors, RT in, See also Radiation therapy (RT), in melanoma stage IV algorithm for, introduction, surgical treatment of, as adjuvant therapy, M1a disease, M1b disease, 1079 M1c disease, preoperative planning for, surviving, introduction, prognostic factors in, surveillance in, NCCN Guidelines, patient education and risk factor modification, 996 psychosocial distress evaluation and coping mechanisms, 997 tailoring schedules to individual patient needs, 996 variations in follow-up practices, 993 systemic therapy in, See also Systemic therapy, in melanoma unusual presentations of, cutaneous melanoma arising in childhood, introduction, 1060 melanoma arising in eye, arising on mucosal surfaces, unknown primary melanoma in dermis and subcutaneous tissue, in regional nodes, in visceral organs, vaccines for, See also Vaccine(s), melanoma wild-type algorithm for, Mohs surgery in HNM management, 1108 Molecularly targeted therapies in melanoma, Mucosal surfaces melanoma arising on, N Neurotropic melanoma RT for, 1033

6 1132 Index Non-Caucasian populations melanoma in, See also Melanoma, in non-caucasian populations O Older persons melanoma in, 948 P Primary cutaneous melanoma management of, background of, 974 intermediate-thickness melanoma, 975 melanoma in situ, 976 thick melanoma, 976 thin melanoma, PV-10/rose bengal in melanoma, 1009 R Race as factor in melanoma, Radiation therapy (RT) for HNM, 1100 in melanoma, , introduction, 1031 for local control, anorectal melanoma, 1035 desmoplastic and neurotropic melanoma, 1033 head and neck mucosal melanoma, high-risk cutaneous melanoma, LM, 1032 for nodal basin control, adjuvant radiation, morbidity data, risk factors for nodal basin recurrence, Regional lymph nodes management of, background, 976 elective lymphadenectomy in, indications for, LND in, SLEB in, technical points, unknown primary melanoma in, See also Unknown primary melanoma, in regional nodes RT. See Radiation therapy (RT) S Sentinel lymph node biopsy (SLNB) for HNM,

7 Index 1133 in regional lymph nodes management, , clinical evidence for, in workup and staging of malignant melanoma, SLNB. See Sentinel lymph node biopsy (SLNB) Socioeconomic status melanoma related to, Subcutaneous tissue unknown primary melanoma in, Systemic therapy in melanoma, 1010, adjuvant therapy, clinical trials, interferon results, algorithm for stage IV melanoma, immunotherapy, introduction, molecularly targeted therapies, relevant biology related to, T T-VEC. See Talimogene laherparepvec (T-VEC) Talimogene laherparepvec (T-VEC) in melanoma, Topical agents in melanoma, 1010 U Ultrasound in workup and staging of malignant melanoma, Ultraviolet (UV) light melanoma related to, Unknown primary melanoma in dermis and subcutaneous tissue, in regional nodes, initial evaluation of, management of adjuvant therapy in, surgical, 1061 relevant biology of, 1061 in visceral organs, Unusual presentations of melanoma, See also specific types and Melanoma, unusual presentations of V Vaccine(s) melanoma, allogeneic,

8 1134 Index Vaccine(s) (continued) autologous, future directions in, ganglioside, 1023 immune adjuvants and immunomodulators, intralesional immunotherapy, 1026 introduction, peptide, Visceral organs unknown primary melanoma in,